In a separate study that evaluated patient perceptions of the injection devices for liraglutide and dulaglutide, the dulaglutide device was associated with a slightly higher score for ease of use and convenience [128]
While GLP-1 primarily supports appetite control, GIP enhances insulin sensitivity, improves how the body utilizes energy, and supports healthier fat metabolism
Ruttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)